Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities
otherwise, see the standalone overviews)
Research indicates dopamine antagonists can impair sphincter function, while BPC-157 counteracts these effects
A previous study has shown that MOTS-c intervention significantly ameliorates bone loss in 8-week-old C57BL/6 female ovariectomized mice by inhibiting osteoclast formation in an AMPK-dependent manner to prevent ovariectomy-induced bone loss (Ming et al., 2016)
Plus it's affordable
suggest that GH impacts adipose tissue in a depot-specific manner and impacts other features of adipose tissue (for example, senescence, adipocyte subpopulations, and fibrosis), all of which [may] impact lipolysis